BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26251519)

  • 1. HMGA1 overexpression is associated with a particular subset of human breast carcinomas.
    Sepe R; Piscuoglio S; Quintavalle C; Perrina V; Quagliata L; Formisano U; Terracciano LM; Fusco A; Pallante P
    J Clin Pathol; 2016 Feb; 69(2):117-21. PubMed ID: 26251519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression.
    Chiappetta G; Botti G; Monaco M; Pasquinelli R; Pentimalli F; Di Bonito M; D'Aiuto G; Fedele M; Iuliano R; Palmieri EA; Pierantoni GM; Giancotti V; Fusco A
    Clin Cancer Res; 2004 Nov; 10(22):7637-44. PubMed ID: 15569996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia.
    Arafah M
    Turk Patoloji Derg; 2012; 28(1):38-43. PubMed ID: 22207430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: true or false?
    Saatee S; Afrakhteh M; Sadrolhefazi B
    Breast J; 2006; 12(5):499-501. PubMed ID: 16958978
    [No Abstract]   [Full Text] [Related]  

  • 5. Utility of Sox10 labeling in metastatic breast carcinomas.
    Nelson ER; Sharma R; Argani P; Cimino-Mathews A
    Hum Pathol; 2017 Sep; 67():205-210. PubMed ID: 28843711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
    Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
    Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
    Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
    Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Her-2 amplification and p185 expression in invasive breast cancer cells in women].
    Titi S
    Ann Acad Med Stetin; 2006; 52(2):5-12. PubMed ID: 17633393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of oestrogen receptor-beta in invasive breast tumours].
    Péter I; Számel I; Péley G
    Magy Onkol; 2004; 48(1):63-9. PubMed ID: 15105898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of HER-2/NEU oncoprotein in familial and non-familial breast cancer.
    Tsai KB; Hou MF; Lin HJ; Chai CY; Liu CS; Huang TJ
    Kaohsiung J Med Sci; 2001 Feb; 17(2):64-76. PubMed ID: 11416960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing frequency of equivocal HER-2/neu scores and factors predictive of negative HER 2/neu fluorescent in situ hybridisation in invasive carcinomas of the breast.
    Boulos F; Farra CG; Saad Aldin EM; Masaad C; Hassoun Y; Fedda F; Doumiati H; Tawil AN; Nasser Z; Nahleh Z; Tfayli A
    J Clin Pathol; 2014 Mar; 67(3):204-9. PubMed ID: 24108431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER-2 protein overexpressing breast cancer without gene amplification shows higher hormone receptor expression than HER-2 protein overexpressing breast cancer with gene amplification.
    Koo JS; Jung W; Yang WI
    Int J Surg Pathol; 2011 Aug; 19(4):425-32. PubMed ID: 19666946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biological features of breast cancer in patients under 35].
    Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
    Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitotic index matter: how to improve the assessment of mitosis in order to better classify G2 breast cancer and luminal A category.
    Del Sordo R; Bellezza G; Ferri I; Pireddu A; Colella R; Sidoni A
    Histol Histopathol; 2018 Jan; 33(1):81-88. PubMed ID: 28332699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant elevation of CLDN16 and HAPLN3 gene expression in human breast cancer.
    Kuo SJ; Chien SY; Lin C; Chan SE; Tsai HT; Chen DR
    Oncol Rep; 2010 Sep; 24(3):759-66. PubMed ID: 20664984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of HER 2/neu gene amplification with immunohistochemistry and other prognostic factors in breast carcinoma.
    Ramadan SS; Yapicier O; Kıhtır S; Erdemır A; Doğan TH; Uskent I; Onat H; Cakmakçi M
    Turk Patoloji Derg; 2011; 27(3):196-203. PubMed ID: 21935868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R; Apple SK; He J; Gornbein JA; Chang HR
    Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of sarcosine metabolism-related proteins in estrogen receptor negative breast cancer according to the androgen receptor and HER-2 status.
    Kim MJ; Jung WH; Koo JS
    Int J Clin Exp Pathol; 2015; 8(7):7967-77. PubMed ID: 26339363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
    Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and correlation of molecular subtypes of breast cancer with clinicopathological features.
    Akbar M; Akbar K; Naveed D
    J Ayub Med Coll Abbottabad; 2014; 26(3):290-3. PubMed ID: 25671929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.